Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
Subscribe To Our Newsletter & Stay Updated
